Analyst consensus rating
Neurocrine Biosciences Analyst Rating: Strong Buy
Direct answer
Neurocrine Biosciences's consensus rating is Strong Buy.
28 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $208.54.
Forecast evidence checked November 17, 2026.
Get free Neurocrine Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $165.31
- Average price target
- $208.54
- High price target
- $253.00
- Low price target
- $150.00
- Low target gap
- -9.3%
- Target upside
- +26.2%
- High target gap
- +53%
- Target range width
- 62.3%
- Consensus rating
- Strong Buy
- Analysts
- 28
- Evidence date
- November 17, 2026
- Valid through
- November 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Neurocrine Biosciences?
Neurocrine Biosciences has a verified Strong Buy consensus. The same dataset has an average price target of $208.54.
How far are Neurocrine Biosciences's low and high targets from the recorded price?
The low target implies -9.3%, while the high target implies +53%.
How many analysts are included in Neurocrine Biosciences's consensus?
The verified consensus includes 28 analysts.
How is Neurocrine Biosciences's target upside or downside calculated?
The average target of $208.54 is divided by the recorded price of $165.31, then one is subtracted to produce +26.2%. This does not guarantee a future return.
When was Neurocrine Biosciences's analyst forecast verified?
The data was verified on 2026-11-17. The dataset is valid through 2026-11-24.